The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

(2018) V. Cox et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

(2018) Nafees Ahmad et al.   LANCET

Classifying new anti-tuberculosis drugs: rationale and future perspectives

(2017) Simon Tiberi et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

(2017) A. Reuter et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Adverse Events Associated with Treatment of Multidrug-Resistant Tuberculosis in China: An Ambispective Cohort Study

(2017) Yang Zhang et al.   MEDICAL SCIENCE MONITOR

Landmark legal ruling sees Indian girl prescribed bedaquiline for XDR-TB

(2017) Tony Kirby   Lancet Respiratory Medicine

The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan

(2016) Susan van den Hof et al.   BMC INFECTIOUS DISEASES

A Bayesian response-adaptive trial in tuberculosis: The endTB trial

(2016) Matteo Cellamare et al.   Clinical Trials

Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis

(2016) Lorenzo Guglielmetti et al.   EUROPEAN RESPIRATORY JOURNAL

Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial

(2016) M. Cellamare et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Classification of antituberculosis drugs: a new proposal based on the most recent evidence

(2015) Jose A. Caminero et al.   EUROPEAN RESPIRATORY JOURNAL

Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives

(2015) Erica Lessem et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa

(2015) L. Ramma et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis

(2015) Kwonjune J. Seung et al.   Cold Spring Harbor Perspectives in Medicine

Pharmacovigilance and tuberculosis: applying the lessons of thioacetazone

(2014) Dennis Falzon et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India

(2014) Z. F. Udwadia et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

(2014) Andreas H. Diacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa

(2013) Karen Shean et al.   PLoS One

Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements to meet 2015 targets

(2013) Katherine Floyd et al.   Lancet Global Health

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

(2012) Vija Skripconoka et al.   EUROPEAN RESPIRATORY JOURNAL

New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future

(2012) Christian Lienhardt et al.   JOURNAL OF INFECTIOUS DISEASES